Saniona Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 0/6

Saniona şirketinin kazançları yıllık ortalama -9.7% oranında azalırken, Biotechs sektörünün kazançları yıllık 13.4% oranında artan oldu. Gelirler yıllık ortalama 3.7% oranında artan oldu.

Anahtar bilgiler

-9.7%

Kazanç büyüme oranı

2.2%

EPS büyüme oranı

Biotechs Sektör Büyümesi	0.7%
Gelir büyüme oranı	3.7%
Özkaynak getirisi	-1,179.8%
Net Marj	-328.8%
Sonraki Kazanç Güncellemesi	28 Nov 2024

Yakın geçmiş performans güncellemeleri

Recent updates

What Type Of Shareholders Make Up Saniona AB (publ)'s (STO:SANION) Share Registry?

Jan 06

Is Saniona (STO:SANION) Using Too Much Debt?

Dec 02

Gelir ve Gider Dağılımı

Saniona nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.

Kazanç ve Gelir Geçmişi

OM:SANION Gelir, gider ve kazançlar (SEK Millions )
Tarih	Gelir	Kazançlar	G+A Giderleri
30 Jun 24	25	-82	76
31 Mar 24	21	-83	77
31 Dec 23	17	-96	81
30 Sep 23	15	-108	52
30 Jun 23	12	-33	44
31 Mar 23	11	-100	113
31 Dec 22	15	-212	229
30 Sep 22	15	-334	330
30 Jun 22	15	-445	439
31 Mar 22	14	-461	450
31 Dec 21	10	-411	409
30 Sep 21	9	-326	352
30 Jun 21	9	-280	300
31 Mar 21	9	-200	225
31 Dec 20	8	-73	160
30 Sep 20	11	-25	113
30 Jun 20	9	-5	102
31 Mar 20	8	-1	95
31 Dec 19	7	-69	95
30 Sep 19	5	-96	110
30 Jun 19	49	-53	108
31 Mar 19	52	-52	115
31 Dec 18	55	-41	104
30 Sep 18	57	-32	89
30 Jun 18	17	-61	85
31 Mar 18	17	-56	79
31 Dec 17	21	-49	74
30 Sep 17	21	-47	74
30 Jun 17	68	-6	71
31 Mar 17	67	-2	67
31 Dec 16	75	2	69
30 Sep 16	71	10	56
30 Jun 16	23	-25	52
31 Mar 16	25	-21	46
31 Dec 15	14	-23	39
30 Sep 15	16	-23	41
30 Jun 15	19	-16	36
31 Mar 15	23	-10	33
31 Dec 14	22	-6	27
31 Dec 13	13	-1	14

Kaliteli Kazançlar: SANION şu anda kârlı değil.

Büyüyen Kar Marjı: SANION şu anda kârlı değil.

Serbest Nakit Akışı ve Kazanç Analizi

Geçmiş Kazanç Büyüme Analizi

Kazanç Eğilimi: SANION kârlı değildir ve zararlar son 5 yılda yılda 9.7% oranında artmıştır.

Büyüme Hızlandırma: SANION 'un son bir yıldaki kazanç büyümesinin 5 yıllık ortalamasıyla karşılaştırılması mümkün değil çünkü şu anda kârlı değil

Kazançlar vs. Sektör: SANION kârlı olmadığından, geçmiş yıl kazanç büyümesinin Biotechs sektörüyle ( -18.6% ) karşılaştırılması zorlaşıyor.

Özkaynak Getirisi

Yüksek ROE: SANION hissesi şu anda kârlı olmadığından negatif Özsermaye Getirisi'ne ( -1179.78% ) sahiptir.

Saniona Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 0/6

Anahtar bilgiler

Yakın geçmiş performans güncellemeleri

Second quarter 2024 earnings released: kr0.18 loss per share (vs kr0.34 loss in 2Q 2023)

First quarter 2024 earnings released: kr0.08 loss per share (vs kr0.35 loss in 1Q 2023)

Saniona AB (publ) to Report Fiscal Year 2023 Results on Apr 30, 2024

Full year 2023 earnings released: kr1.49 loss per share (vs kr3.93 loss in FY 2022)

Third quarter 2023 earnings released: kr0.38 loss per share (vs kr0.28 profit in 3Q 2022)

Saniona AB (publ) to Report Fiscal Year 2024 Results on Feb 27, 2025

Recent updates

Saniona Initiates SAN711 Biomarker Study

Saniona Receives Regulatory Approval for San711 Biomarker Study

New major risk - Financial position

Second quarter 2024 earnings released: kr0.18 loss per share (vs kr0.34 loss in 2Q 2023)

Is Saniona (STO:SANION) Weighed On By Its Debt Load?

New minor risk - Share price stability

First quarter 2024 earnings released: kr0.08 loss per share (vs kr0.35 loss in 1Q 2023)

Saniona AB (publ) to Report Fiscal Year 2023 Results on Apr 30, 2024

Full year 2023 earnings released: kr1.49 loss per share (vs kr3.93 loss in FY 2022)

New major risk - Shareholder dilution

Price target decreased by 37% to kr6.00

Saniona Announces the Selection of Its Proprietary GABAA A5 Negative Allosteric Modulator (NAM) Lead Compound, San2465

Saniona AB (publ) Strengthens Epilepsy Pipeline with Selection of SAN2355 as Clinical Candidate

Third quarter 2023 earnings released: kr0.38 loss per share (vs kr0.28 profit in 3Q 2022)

Saniona AB (publ) to Report Fiscal Year 2024 Results on Feb 27, 2025

Saniona AB (publ), Annual General Meeting, May 29, 2024

Saniona (STO:SANION) Is Making Moderate Use Of Debt

Saniona Promotes Kv7 Epilepsy Compound to Candidate Selection Phase

Second quarter 2023 earnings released: kr0.34 loss per share (vs kr1.42 loss in 2Q 2022)

New minor risk - Shareholder dilution

Is Saniona (STO:SANION) Using Too Much Debt?

First quarter 2023 earnings released: kr0.35 loss per share (vs kr2.14 loss in 1Q 2022)

Full year 2022 earnings released: kr3.93 loss per share (vs kr6.59 loss in FY 2021)

Saniona AB Appoints Nomination Committee for the Annual General Meeting 2023

Third quarter 2022 earnings released: EPS: kr0.28 (vs kr1.50 loss in 3Q 2021)

Saniona AB (publ) to Report Q1, 2023 Results on May 25, 2023

Insufficient new directors

Saniona AB (publ) Announces Anti-Inflammatory and Anti-Fibrotic Candidate SAN903 Is Ready for Clinical Studies

Second quarter 2022 earnings released: kr1.42 loss per share (vs kr1.67 loss in 2Q 2021)

Saniona Progresses Its Kv7 Epilepsy Program into Lead Optimization

Saniona Reports Positive Top Line Results from the SAN711 Phase 1 Clinical Trial

Insufficient new directors

Saniona’S Preclinical Candidate San903 Shows Robust Dampening of Fibrosis in Chronic Kidney Disease Model

Saniona Provides Update on Ongoing Review of Tesofensine in Mexico

Saniona Appoints Anita Milland as Chief Financial Officer, Effective April 30, 2022

Saniona Announces Voluntary Pause of Phase 2B Clinical Trials of Tesomet for Hypothalamic Obesity and Prader-Willi Syndrome

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Saniona AB (publ) to Report Fiscal Year 2021 Final Results on Apr 29, 2022

Saniona Initiates Multiple Ascending Dose Stage of SAN711 Phase 1 Clinical Trial

Saniona Initiates Phase 2b Clinical Trial of Tesomet for Prader-Willi Syndrome

President & CEO recently bought kr100k worth of stock

Independent Chairman of the Board recently bought kr229k worth of stock

Third quarter 2021 earnings released: kr1.50 loss per share (vs kr1.24 loss in 3Q 2020)

Second quarter 2021 earnings released: kr1.67 loss per share (vs kr1.24 loss in 2Q 2020)

Saniona Initiates Phase 1 Clinical Trial of SAN711

Saniona to Present Preclinical Data on SAN711 at the 7th Congress of the European Academy of Neurology

First quarter 2021 earnings released: kr1.34 loss per share (vs kr1.47 profit in 1Q 2020)

Full year 2020 earnings released: kr1.79 loss per share (vs kr2.95 loss in FY 2019)

Is Saniona (STO:SANION) Using Too Much Debt?

Saniona Receives Feedback from U.S. FDA Providing a Regulatory Path Forward for Tesomet in Hypothalamic Obesity

Saniona Receives U.S. FDA Orphan Drug Designation for Tesomet in Prader-Willi Syndrome

New 90-day low: kr18.70

Need To Know: Saniona AB (publ) (STO:SANION) Insiders Have Been Buying Shares

Novartis AG (SWX:NOVN) completed the acquisition of Cadent Therapeutics, Inc. from a group of sellers.

New 90-day low: kr20.10

What Type Of Shareholders Make Up Saniona AB (publ)'s (STO:SANION) Share Registry?

New 90-day low: kr20.70

Saniona Announces Management Appointments

Co-Founder recently bought kr108k worth of stock

Co-Founder recently bought kr115k worth of stock

New 90-day low: kr22.55

Is Saniona (STO:SANION) Using Too Much Debt?

Third quarter 2020 earnings released: kr1.24 loss per share

Saniona AB (publ) to Report Fiscal Year 2021 Results on Feb 24, 2022

Saniona AB (publ) Appoints Nomination Committee Members

Saniona Reports Positive Topline Results from Tesomet Phase 2 Open-Label Extension Study in Hypothalamic Obesity

New 90-day low: kr24.70

Saniona Receives Pre-IND Feedback from FDA on Regulatory Path for Tesomet in Prader-Willi Syndrome (PWS) and Hypothalamic Obesity (HO)

Earnings released